BioCentury
ARTICLE | Emerging Company Profile

MethylGene: Making multiple bets

October 26, 1998 8:00 AM UTC

MethylGene Inc. believes in mitigating risk by taking multiple approaches to developing drugs for a given target, while also developing them in as many indications as possible. MethylGene's primary objective, said President and CEO Donald Corcoran, is to "get a target and take multiple cuts at it" using the company's three therapeutic development platforms: antisense, hairpin oligonucleotides and rationally designed small molecules.

Corcoran said MethylGene got its start when he was vice president of international operations and business development at Hybridon Inc. HYBN (Cambridge, Mass.) could not sustain all of it development projects, so it went shopping for partners...